Table of Contents
ISRN Oncology
Volume 2012, Article ID 163752, 15 pages
http://dx.doi.org/10.5402/2012/163752
Review Article

Biologic Therapy in Head and Neck Cancer: A Road with Hurdles

Department of Medical Oncology, Antwerp University Hospital, Wilrijkstraat 10, 2650 Edegem, Belgium

Received 11 March 2012; Accepted 11 April 2012

Academic Editors: A. Celetti, K. J. Dornfeld, and F. Kuhnel

Copyright © 2012 Pol Specenier and Jan B. Vermorken. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. http://globocan.iarc.fr.
  2. R. I. Haddad and D. M. Shin, “Recent advances in head and neck cancer,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1143–1154, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. http://www.cancer.gov/clinicaltrials/search.
  4. J. R. Grandis and D. J. Tweardy, “Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer,” Cancer Research, vol. 53, no. 15, pp. 3579–3584, 1993. View at Google Scholar · View at Scopus
  5. K. K. Ang, B. A. Berkey, X. Tu et al., “Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma,” Cancer Research, vol. 62, no. 24, pp. 7350–7356, 2002. View at Google Scholar · View at Scopus
  6. C. H. Chung, K. Ely, L. McGavran et al., “Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas,” Journal of Clinical Oncology, vol. 24, no. 25, pp. 4170–4176, 2006. View at Publisher · View at Google Scholar · View at Scopus
  7. A. N. Demiral, S. Sarioglu, B. Birlik, M. Sen, and M. Kinay, “Prognostic significance of EGF receptor expression in early glottic cancer,” Auris Nasus Larynx, vol. 31, no. 4, pp. 417–424, 2004. View at Publisher · View at Google Scholar · View at Scopus
  8. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000558/WC500029119.pdf.
  9. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/125084s168lbl.pdf.
  10. J. Marshall, “Clinical implications of the mechanism of epidermal growth factor receptors inhibitors,” Cancer, vol. 107, no. 6, pp. 1207–1218, 2006. View at Publisher · View at Google Scholar · View at Scopus
  11. H. Modjtahedi, “Molecular therapy of head and neck cancer,” Cancer and Metastasis Reviews, vol. 24, no. 1, pp. 129–146, 2005. View at Publisher · View at Google Scholar · View at Scopus
  12. R. Mehra, R. B. Cohen, and B. A. Burtness, “The role of cetuximab for the treatment of squamous cell carcinoma of the head and neck,” Clinical Advances in Hematology and Oncology, vol. 6, no. 10, pp. 742–750, 2008. View at Google Scholar · View at Scopus
  13. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival,” The Lancet Oncology, vol. 11, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  14. J. A. Bonner, P. M. Harari, J. Giralt et al., “Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck,” The New England Journal of Medicine, vol. 354, no. 6, pp. 567–578, 2006. View at Publisher · View at Google Scholar · View at Scopus
  15. J. P. Pignon, J. Bourhis, C. Domenge, and L. Designé, “Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC collaborative group. meta-analysis of chemotherapy on head and neck cancer,” The Lancet, vol. 355, no. 9208, pp. 949–955, 2000. View at Google Scholar · View at Scopus
  16. J. P. Pignon, A. L. Maître, E. Maillard, and J. Bourhis, “Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients,” Radiotherapy & Oncology, vol. 92, no. 1, pp. 4–14, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. K. K. Ang, Q. Zhang, D. I. Rosenthal et al., “A randomized phase III trial (RTOG 0522) of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III-IV head and neck squamous cell carcinomas (HNC),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5500, 2011. View at Google Scholar
  18. J. L. Lefebvre, Y. Pointreau, F. Rolland et al., “Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): results of the randomized phase II TREMPLIN study,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5501, 2011. View at Google Scholar
  19. T. Y. Seiwert, D. J. Haraf, E. E. Cohen et al., “A randomized phase II trial of cetuximab-based induction chemotherapy followed by concurrent cetuximab, 5-FU, hydroxyurea, and hyperfractionated radiation (CetuxFHX), or cetuximab, cisplatin, and accelerated radiation with concomitant boost (CetuxPX) in patients with locoregionally advanced head and neck cancer (HNC),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5519, 2011. View at Google Scholar
  20. A. Argiris, M. V. Karamouzis, R. Smith et al., “Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer,” Annals of Oncology, vol. 22, no. 11, pp. 2482–2488, 2011. View at Google Scholar
  21. H. Wanebo, M. S. Ghebremichael, B. A. Burtness et al., “Phase II induction cetuximab (C225), paclitaxel (P), and carboplatin (C) followed by chemoradiation with C225, P, C, and RT 68-72Gy for stage III/IV head and neck squamous cancer: primary site organ preservation and disease control at 2 years (ECOG, E2303),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5513, 2010. View at Google Scholar
  22. W. Jordan, I. Wildfang, H. Welkoborsky et al., “TPF induction-radioimmunochemotherapy for the treatment of advanced head and neck cancer,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5514, 2010. View at Google Scholar
  23. R. L. Ferris, D. E. Heron, S. Kim et al., “Induction docetaxel, cisplatin, and cetuximab (TPE) followed by concurrent radiotherapy, cisplatin, and cetuximab and maintenance cetuximab in patients with locoregionally advanced head and neck cancer (HNC): Mature results with HPV analysis,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5515, 2010. View at Google Scholar
  24. R. Mesia, A. Rueda, R. Vera et al., “Is there a role for adjuvant cetuximab after radiotherapy (RT) plus cetuximab in patients (pts) with locally advanced squamous cell carcinoma of the oropharynx? A phase II randomized trial,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5534, 2010. View at Google Scholar
  25. J. B. Vermorken, R. Mesia, F. Rivera et al., “Platinum-based chemotherapy plus cetuximab in head and neck cancer,” The New England Journal of Medicine, vol. 359, no. 11, pp. 1116–1127, 2008. View at Publisher · View at Google Scholar · View at Scopus
  26. B. Burtness, M. A. Goldwasser, W. Flood, B. Mattar, and A. A. Forastiere, “Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern cooperative oncology group study,” Journal of Clinical Oncology, vol. 23, no. 34, pp. 8646–8654, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Hitt, A. Irigoyen, H. Cortes-Funes, J. J. Grau, J. A. Garcia-Saenz, and J. J. Cruz-Hernandez, “Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck,” Annals of Oncology, vol. 23, no. 4, pp. 1016–1022, 2012. View at Publisher · View at Google Scholar
  28. J. Guigay, J. Fayette, A. F. Dillies et al., “Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): first results of phase II trial GORTEC 2008-03,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5567, 2011. View at Google Scholar
  29. I. Tinhofer, K. Klinghammer, W. Weichert et al., “Interference of amphiregulin and EGFRvIII expression with outcome of patients with squamous cell carcinoma of the head and neck (SCCHN) receiving cetuximab-docetaxel treatment,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5508, 2011. View at Google Scholar · View at Scopus
  30. J. Baselga, J. M. Trigo, J. Bourhis et al., “Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5568–5577, 2005. View at Publisher · View at Google Scholar · View at Scopus
  31. R. S. Herbst, M. Arquette, D. M. Shin et al., “Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 23, no. 24, pp. 5578–5587, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. J. B. Vermorken, J. Trigo, R. Hitt et al., “Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy,” Journal of Clinical Oncology, vol. 25, no. 16, pp. 2171–2177, 2007. View at Publisher · View at Google Scholar · View at Scopus
  33. J. B. Vermorken, R. S. Herbst, X. Leon, N. Amellal, and J. Baselga, “Overview of the efficacy of cetuximab in recurrent and/or metastatic squamous cell carcinoma of the head and neck in patients who previously failed platinum-based therapies,” Cancer, vol. 112, no. 12, pp. 2710–2719, 2008. View at Publisher · View at Google Scholar · View at Scopus
  34. X. León, R. Hitt, M. Constenla et al., “A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy,” Clinical Oncology, vol. 17, no. 6, pp. 418–424, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. M. Fury, E. J. Sherman, D. M. Lisa et al., “A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5563, 2011. View at Google Scholar
  36. J. P. Machiels, S. Subramanian, A. Ruzsa et al., “Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial,” The Lancet Oncology, vol. 12, no. 4, pp. 333–343, 2011. View at Publisher · View at Google Scholar · View at Scopus
  37. J. B. Vermorken, J. Stöhlmacher, I. Davidenko et al., “Primary efficacy and safety results of SPECTRUM, a phase 3 trial of recurrent and/or metastatic squamous cell carcinoma of the head and neck receiving chemotherapy with or without panitumumab,” Annals of Oncology, vol. 21, supplement 8, abstract no. LBA26, 2010. View at Publisher · View at Google Scholar
  38. M. Gupta, V. Madholia, and K. T. Bhowmik, “Results from a pilot study of nimotuzumab with concurrent chemoradiation in patients with locally advanced squamous cell carcinoma of head and neck,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5565, 2010. View at Google Scholar
  39. M. O. Rodríguez, T. C. Rivero, B. R. del Castillo et al., “Nimotuzumab plus radiotherapy for unresectable squamous-cell carcinoma of the head and neck,” Cancer Biology and Therapy, vol. 9, no. 5, pp. 343–349, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. K. G. Babu, L. Viswanath, B. K. Reddy et al., “An open-label, randomized, study of h-R3mAb (nimotuzumab) in patients with advanced (stage III or IVa) squamous cell carcinoma of head and neck (SCCHN): four-year survival results from a phase IIb study,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5530, 2010. View at Google Scholar
  41. A. Argiris, M. S. Ghebremichael, J. Gilbert, B. A. Burtness, and A. A. Forastiere, “A phase III randomized, placebo-controlled trial of docetaxel (D) with or without gefitinib (G) in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): a trial of the Eastern cooperative oncology group (ECOG),” Journal of Clinical Oncology, vol. 27, no. 15, supplement, abstract no. 6011, 2009. View at Google Scholar
  42. J. S. Stewart, E. E. Cohen, L. Licitra et al., “Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 27, no. 11, pp. 1864–1871, 2009. View at Publisher · View at Google Scholar · View at Scopus
  43. E. E. Cohen, F. Rosen, W. M. Stadler et al., “Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1980–1987, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. E. E. Cohen, M. A. Kane, M. A. List et al., “Phase II trial of gefitinib 250 mg daily in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Clinical Cancer Research, vol. 11, no. 23, pp. 8418–8424, 2005. View at Publisher · View at Google Scholar · View at Scopus
  45. A. M. Kirby, R. P. A'Hern, C. D'Ambrosio et al., “Gefitinib (ZD1839, Iressa) as palliative treatment in recurrent or metastatic head and neck cancer,” British Journal of Cancer, vol. 94, no. 5, pp. 631–636, 2006. View at Publisher · View at Google Scholar · View at Scopus
  46. D. Soulieres, N. N. Senzer, E. E. Vokes, M. Hidalgo, S. S. Agarvala, and L. L. Siu, “Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck,” Journal of Clinical Oncology, vol. 22, no. 1, pp. 77–85, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. C. A. Perez, H. Song, L. E. Raez, M. Agulnik, T. A. Grushko, and A. Dekker, “Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent and/or metastatic squamous cell carcinoma of the head and neck,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5517, 2011. View at Google Scholar
  48. W. N. William Jr., R. S. Weber, J. J. Lee, J. Myers, L. E. Ginsberg, and A. K. El-Naggar, “Randomized trial of a short course of erlotinib 150 to 300 mg daily prior to surgery for squamous cell carcinomas of the head and neck (SCCHN) in current, former, and never smokers: objective responses and clinical outcomes,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5520, 2011. View at Google Scholar
  49. D. N. Hayes, L. E. Raez, A. K. Sharma et al., “Multicenter randomized phase II trial of combined radiotherapy and cisplatin with or without erlotinib in patients with locally advanced squamous cell carcinoma of the head and neck (SCCAHN): preliminary toxicity results,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5580, 2010. View at Google Scholar
  50. V. Gregoire, M. Hamoir, C. Chen et al., “Gefitinib plus cisplatin and radiotherapy in previously untreated head and neck squamous cell carcinoma: a phase II, randomized, double-blind, placebo-controlled study,” Radiotherapy & Oncology, vol. 100, no. 1, pp. 62–69, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. Soulieres, B. Fortin, E. Winquist, D. Charpentier, E. Harnett, and W. Parulekar, “HN5: a phase I/II study of erlotinib as adjuvant therapy in patients treated by chemoradiation therapy (CRT) for locally advanced SCCHN,” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5562, 2010. View at Google Scholar
  52. T. Y. Seiwert, J. Fayette, J. M. Del Campo et al., “Updated results of a randomized, open-label phase II study exploring BIBW 2992 versus cetuximab in patients with platinum-refractory metastatic/reciurrent head and neck cancer (SCCHN),” Annals of Oncology, vol. 21, supplement 8, abstract no. 1010PD, 2010. View at Google Scholar
  53. K. J. Harrington, A. Berrier, M. Robinson et al., “Phase II study of oral lapatinib, a dual-tyrosine kinase inhibitor, combined with chemoradiotherapy (CRT) in patients (pts) with locally advanced, unresected squamous cell carcinoma of the head and neck (SCCHN),” Journal of Clinical Oncology, vol. 15, supplement, abstract no. 5505, 2010. View at Google Scholar
  54. J. M. Del Campo, R. Hitt, P. Sebastian et al., “Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck,” British Journal of Cancer, vol. 105, no. 5, pp. 618–627, 2011. View at Publisher · View at Google Scholar · View at Scopus
  55. L. L. Siu, S. J. Hotte, S. A. Laurie et al., “Phase II trial of the irreversible oral pan-human EGF receptor (HER) inhibitor PF-00299804 (PF) as first-line treatment in recurrent and/or metastatic (RM) squamous cell carcinoma of the head and neck (SCCHN),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5561, 2011. View at Google Scholar
  56. P. A. Kyzas, I. W. Cunha, and J. P. Ioannidis, “Prognostic significance of vascular endothelial growth factor immunohistochemical expression in head and neck squamous cell carcinoma: a meta-analysis,” Clinical Cancer Research, vol. 11, no. 4, pp. 1434–1440, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. S. Cao, F. A. Durrani, K. Toth, Y. M. Rustum, and M. Seshadri, “Bevacizumab enhances the therapeutic efficacy of irinotecan against human head and neck squamous cell carcinoma xenografts,” Oral Oncology, vol. 47, no. 6, pp. 459–466, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. K. Fujita, D. Sano, M. Kimura et al., “Anti-tumor effects of bevacizumab in combination with paclitaxel on head and neck squamous cell carcinoma,” Oncology Reports, vol. 18, no. 1, pp. 47–51, 2007. View at Google Scholar · View at Scopus
  59. A. Argiris, M. V. Karamouzis, W. E. Gooding et al., “Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer,” Journal of Clinical Oncology, vol. 29, no. 9, pp. 1140–1145, 2011. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Y. Seiwert, D. J. Haraf, E. E. Cohen et al., “Phase I study of bevacizumab added to fluorouracil- and hydroxyurea-based concomitant chemoradiotherapy for poor-prognosis head and neck cancer,” Journal of Clinical Oncology, vol. 26, no. 10, pp. 1732–1741, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. J. K. Salama, D. J. Haraf, K. M. Stenson et al., “A randomized phase II study of 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy compared with bevacizumab plus 5-fluorouracil, hydroxyurea, and twice-daily radiotherapy for intermediate-stage and T4N0-1 head and neck cancers,” Annals of Oncology, vol. 22, no. 10, pp. 2304–2309, 2011. View at Google Scholar
  62. P. Harari, D. Khuntia, A. M. Traynor, J. K. Hoang, D. J. Yang, and G. K. Hartig, “Phase I trial of bevacizumab combined with concurrent chemoradiation for squamous cell carcinoma of the head and neck: preliminary outcome results,” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5518, 2011. View at Google Scholar
  63. C. Elser, L. L. Siu, E. Winquist et al., “Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3766–3773, 2007. View at Publisher · View at Google Scholar · View at Scopus
  64. S. K. Williamson, J. Moon, C. H. Huang et al., “Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01,” Journal of Clinical Oncology, vol. 28, no. 20, pp. 3330–3335, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. J. P. Machiels, S. Henry, S. Zanetta et al., “Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01,” Journal of Clinical Oncology, vol. 28, no. 1, pp. 21–28, 2010. View at Publisher · View at Google Scholar · View at Scopus
  66. G. Fountzilas, A. Fragkoulidi, A. Kalogera-Fountzila et al., “A phase II study of sunitinib in patients with recurrent and/or metastatic non-nasopharyngeal head and neck cancer,” Cancer Chemotherapy and Pharmacology, vol. 65, no. 4, pp. 649–660, 2010. View at Google Scholar
  67. N. W. Choong, M. Kozloff, D. Taber et al., “Phase II study of sunitinib malate in head and neck squamous cell carcinoma,” Investigational New Drugs, vol. 28, no. 5, pp. 677–683, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. A. L. Sabichi, M. S. Kies, B. S. Glisson et al., “A phase II study of sorafenib in combination with carboplatin and paclitaxel in patients with metastatic or recurrent squamous cell cancer of the head and neck (SCCHN),” Journal of Clinical Oncology, vol. 28, no. 15, supplement, abstract no. 5532, 2010. View at Google Scholar
  69. D. Sano, F. Matsumoto, D. R. Valdecanas et al., “Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro,” Clinical Cancer Research, vol. 17, no. 7, pp. 1815–1827, 2011. View at Publisher · View at Google Scholar · View at Scopus
  70. D. Sano, M. Kawakami, K. Fujita et al., “Antitumor effects of ZD6474 on head and neck squamous cell carcinoma,” Oncology Reports, vol. 17, no. 2, pp. 289–295, 2007. View at Google Scholar · View at Scopus
  71. V. M. Papadimitrakopoulou, J. V. Heymach, S. J. Frank et al., “Updated clinical and biomarker results from a phase I study of vandetanib with radiation therapy (RT) with or without cisplatin in locally advanced head and neck squamous cell carcinoma (HNSCC),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5510, 2011. View at Google Scholar
  72. T. Okui, T. Shimo, N. M. Hassan et al., “Antitumor effect of novel HSP90 inhibitor NVP-AUY922 against oral squamous cell carcinoma,” Anticancer Research, vol. 31, no. 4, pp. 1197–1204, 2011. View at Google Scholar · View at Scopus
  73. T. Y. Alhazzazi, P. Kamarajan, E. Verdin, and Y. L. Kapila, “SIRT3 and cancer: tumor promoter or suppressor?” Biochimica et Biophysica Acta, vol. 1816, no. 1, pp. 80–88, 2011. View at Publisher · View at Google Scholar · View at Scopus
  74. T. Y. Alhazzazi, P. Kamarajan, N. Joo et al., “Sirtuin-3 (SIRT3), a novel potential therapeutic target for oral cancer,” Cancer, vol. 117, no. 8, pp. 1670–1678, 2011. View at Publisher · View at Google Scholar · View at Scopus
  75. M. Jung, A. Velena, B. Chen, P. A. Petukhov, A. P. Kozikowski, and A. Dritschilo, “Novel HDAC inhibitors with radiosensitizing properties,” Radiation Research, vol. 163, no. 5, pp. 488–493, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. Y. Zhang, M. Jung, A. Dritschilo, and M. Jung, “Enhancement of radiation sensitivity of human squamous carcinoma cells by histone deacetylase inhibitors,” Radiation Research, vol. 161, no. 6, pp. 667–674, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. H. Rikiishi, F. Shinohara, T. Sato, Y. Sato, M. Suzuki, and S. Echigo, “Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid,” International Journal of Oncology, vol. 30, no. 5, pp. 1181–1188, 2007. View at Google Scholar · View at Scopus
  78. T. Sato, M. Suzuki, Y. Sato, S. Echigo, and H. Rikiishi, “Sequence-dependent interaction between cisplatin and histone deacetylase inhibitors in human oral squamous cell carcinoma cells,” International Journal of Oncology, vol. 28, no. 5, pp. 1233–1241, 2006. View at Google Scholar · View at Scopus
  79. R. B. Erlich, Z. Kherrouche, D. Rickwood et al., “Preclinical evaluation of dual PI3K-mTOR inhibitors and histone deacetylase inhibitors in head and neck squamous cell carcinoma,” British Journal of Cancer, vol. 106, no. 1, pp. 107–115, 2011. View at Google Scholar
  80. F. Bruzzese, A. Leone, M. Rocco et al., “HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT,” Journal of Cellular Physiology, vol. 226, no. 9, pp. 2378–2390, 2011. View at Publisher · View at Google Scholar · View at Scopus
  81. E. García-Fernández, J. I. De Diego, E. Collantes-Bellido et al., “Aurora B kinase expression in laryngeal squamous cell carcinoma and its prognostic implications,” Histopathology, vol. 58, no. 3, pp. 368–376, 2011. View at Publisher · View at Google Scholar · View at Scopus
  82. Z. Guan, X. R. Wang, X. F. Zhu et al., “Aurora-A, a negative prognostic marker, increases migration and decreases radiosensitivity in cancer cells,” Cancer Research, vol. 67, no. 21, pp. 10436–10444, 2007. View at Publisher · View at Google Scholar · View at Scopus
  83. G. Pannone, S. A. Hindi, A. Santoro et al., “Aurora B expression as a prognostic indicator and possible therapeutic target in oral squamous cell carcinoma,” International journal of immunopathology and pharmacology, vol. 24, no. 1, pp. 79–88, 2011. View at Google Scholar · View at Scopus
  84. G. Qi, I. Ogawa, Y. Kudo et al., “Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer,” Virchows Archiv, vol. 450, no. 3, pp. 297–302, 2007. View at Publisher · View at Google Scholar · View at Scopus
  85. R. Reiter, P. Gais, U. Jutting et al., “Aurora kinase A messenger RNA overexpression is correlated with tumor progression and shortened survival in head and neck squamous cell carcinoma,” Clinical Cancer Research, vol. 12, no. 17, pp. 5136–5141, 2006. View at Publisher · View at Google Scholar · View at Scopus
  86. H. Zhang, X. Chen, Y. Jin, B. Liu, and L. Zhou, “Overexpression of Aurora-A promotes laryngeal cancer progression by enhancing invasive ability and chromosomal instability,” European Archives of Oto-Rhino-Laryngology, vol. 269, no. 2, pp. 607–614, 2012. View at Publisher · View at Google Scholar · View at Scopus
  87. A. Hoellein, A. Pickhard, F. von Keitz et al., “Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck,” Oncotarget, vol. 2, no. 8, pp. 599–609, 2011. View at Google Scholar
  88. F. Schedel, R. Pries, B. Thode et al., “mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma,” Oncology Reports, vol. 25, no. 3, pp. 763–768, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. K. Y. Chang, S. Y. Tsai, C. M. Wu, C. J. Yen, B. F. Chuang, and J. Y. Chang, “Novel phosphoinositide 3-kinase/mTOR dual inhibitor, NVP-BGT226, displays potent growth-inhibitory activity against human head and neck cancer cells in vitro and in vivo,” Clinical Cancer Research, vol. 17, no. 22, pp. 7116–7126, 2011. View at Google Scholar
  90. S. S. Khariwala, J. Kjaergaard, R. Lorenz, F. Van Lente, S. Shu, and M. Strome, “Everolimus (RAD) inhibits in vivo growth of murine squamous cell carcinoma (SCC VII),” Laryngoscope, vol. 116, no. 5, pp. 814–820, 2006. View at Publisher · View at Google Scholar · View at Scopus
  91. A. A. Molinolo, S. M. Hewitt, P. Amornphimoltham et al., “Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative,” Clinical Cancer Research, vol. 13, no. 17, pp. 4964–4973, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. E. Massarelli, D. D. Liu, J. J. Lee et al., “Akt activation correlates with adverse outcome in tongue cancer,” Cancer, vol. 104, no. 11, pp. 2430–2436, 2005. View at Publisher · View at Google Scholar · View at Scopus
  93. V. Patel, C. A. Marsh, R. T. Dorsam et al., “Decreased lymphangiogenesis and lymph node metastasis by mTOR inhibition in head and neck cancer,” Cancer Research, vol. 71, no. 22, pp. 7103–7112, 2011. View at Google Scholar
  94. A. Bozec, M. C. Etienne-Grimaldi, J. L. Fischel et al., “The mTOR-targeting drug temsirolimus enhances the growth-inhibiting effects of the cetuximab-bevacizumab-irradiation combination on head and neck cancer xenografts,” Oral Oncology, vol. 47, no. 5, pp. 340–344, 2011. View at Publisher · View at Google Scholar · View at Scopus
  95. N. Aissat, C. Le Tourneau, A. Ghoul et al., “Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines,” Cancer Chemotherapy and Pharmacology, vol. 62, no. 2, pp. 305–313, 2008. View at Publisher · View at Google Scholar · View at Scopus
  96. O. Ekshyyan, Y. Rong, X. Rong et al., “Comparison of radiosensitizing effects of the mammalian target of rapamycin inhibitor CCI-779 to cisplatin in experimental models of head and neck squamous cell carcinoma,” Molecular Cancer Therapeutics, vol. 8, no. 8, pp. 2255–2265, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. O. Ekshyyan, G. M. Mills, T. Lian et al., “Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma,” Head & Neck, vol. 32, no. 12, pp. 1619–1628, 2010. View at Publisher · View at Google Scholar · View at Scopus
  98. M. G. Fury, E. Sherman, S. Haque et al., “A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumors,” Cancer Chemotherapy and Pharmacology, vol. 69, no. 3, pp. 591–598, 2012. View at Google Scholar
  99. H. D. Brooks, B. S. Glisson, B. N. Bekele et al., “Phase 2 study of dasatinib in the treatment of head and neck squamous cell carcinoma,” Cancer, vol. 117, no. 10, pp. 2112–2119, 2011. View at Publisher · View at Google Scholar · View at Scopus
  100. M. G. Fury, S. Baxi, R. Shen et al., “Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC),” Anticancer Research, vol. 31, no. 1, pp. 249–253, 2011. View at Google Scholar · View at Scopus
  101. T. Rampias, A. Giagini, K. Florou et al., “H-RAS and PIK3CA mutations and response to cetuximab in head and neck squamous cell carcinoma (HNSCC),” Journal of Clinical Oncology, vol. 29, supplement, abstract no. 5513, 2011. View at Google Scholar
  102. E. E. Cohen, D. W. Davis, T. G. Karrison et al., “Erlotinib and bevacizumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck: a phase I/II study,” The Lancet Oncology, vol. 10, no. 3, pp. 247–257, 2009. View at Publisher · View at Google Scholar · View at Scopus
  103. J. D. Hainsworth, D. R. Spigel, F. A. Greco et al., “Combined modality treatment with chemotherapy, radiation therapy, bevacizumab, and erlotinib in patients with locally advanced squamous carcinoma of the head and neck: a phase II trial of the Sarah Cannon oncology research consortium,” The Cancer Journal, vol. 17, no. 5, pp. 267–272, 2011. View at Google Scholar
  104. J. B. Vermorken, J. Guigay, R. Mesia et al., “Phase I/II trial of cilengitide with cetuximab, cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell cancer of the head and neck: findings of the phase I part,” British Journal of Cancer, vol. 104, no. 11, pp. 1691–1696, 2011. View at Publisher · View at Google Scholar · View at Scopus